Is Tatva Chintan Pharma Chem a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Tatva Chintan Pharma Chem Ltd is a average quality company .

Is Tatva Chintan Pharma Chem undervalued or overvalued?

The key valuation ratios of Tatva Chintan Pharma Chem Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone .

What is Tatva Chintan Pharma Chem share price return in the past 10 years?

Data is not available for this company

Is Tatva Chintan Pharma Chem a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Tatva Chintan Pharma Chem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Tatva Chintan Pharma Chem?

The latest standalone P/E ratio of Tatva Chintan Pharma Chem as of 20-Dec-2024 is 148.71.

What is the P/B ratio of Tatva Chintan Pharma Chem?

The latest standalone P/B ratio of Tatva Chintan Pharma Chem as of 20-Dec-2024 is 2.74.

Tatva Chintan Pharma Chem Ltd - Stock Valuation and Financial Performance

Name: Tatva Chintan Pharma Chem
Brand: Tatva Chintan Pharma Chem

BSE: 543321 | NSE: TATVA | Chemicals | Small Cap

Place order

Tatva Chintan Pharma Share Price

₹845.20 -11.05 -1.29%
as on 20-Dec'24 16:59

10 Year X-Ray of Tatva Chintan Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	26.8%	27.4%	39%	20.4%	22.2%	26.8%	27.9%	25.8%	7.5%	6.9%	-
Value Creation Index ⓘ	0.9	1.0	1.8	0.5	0.6	0.9	1.0	0.8	-0.5	-0.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	102	89.9	109	129	203	254	291	428	403	379	355
Sales YoY Gr.	-	-11.5%	21%	19%	56.8%	25.1%	14.7%	46.9%	-5.8%	-6%	-
Adj EPS ⓘ	2.8	3.6	8	5.1	10.3	17.7	24.1	41.6	20.2	11.5	5.7
YoY Gr.	-	29.2%	120.9%	-36.4%	101.2%	72.8%	35.7%	72.8%	-51.4%	-43.4%	-
BVPS (₹) ⓘ	12.5	16.1	24.7	30.2	39.6	57	80.6	211.5	227.7	310.3	308.4
Adj Net Profit ⓘ	5.7	7.3	16.1	10.3	20.6	35.6	48.3	92.1	44.8	26.8	13
Cash Flow from Ops. ⓘ	5.3	8.7	24.3	12.9	7.9	24.6	18.9	19.8	23.7	103	-
Debt/CF from Ops. ⓘ	3.7	2.4	1.9	4.4	9.8	3.7	4.8	6.1	7.2	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	15.7%	13.3%	9.2%	-6%
Adj EPS ⓘ	16.9%	2.2%	-21.9%	-43.4%
BVPSⓘ	43%	50.9%	56.7%	36.3%
Share Price	-	-	-30.4%	-45.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	27.6	25.4	39.3	18.6	29.4	36.7	35	29.2	9.2	4.4	1.8
Op. Profit Mgn % ⓘ	11.1	16.5	23.7	15.9	17.1	21.1	22.5	24.8	14.3	17.7	10.9
Net Profit Mgn % ⓘ	5.6	8.1	14.8	7.9	10.2	14	16.6	21.5	11.1	7.1	3.7
Debt to Equity ⓘ	0.8	0.7	0.9	0.9	1	0.8	0.6	0.3	0.3	0	0
Working Cap Days ⓘ	141	178	175	189	152	156	190	199	251	256	138
Cash Conv. Cycle ⓘ	40	47	54	76	72	85	106	117	167	175	95

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 1.80%

Sales growth has been subdued in last 3 years 9.15%

Net Profit has been subdued in last 3 years -21.92%

Sales growth is not so good in last 4 quarters at -17.42%

Latest Financials - Tatva Chintan Pharma Chem Ltd.

	Standalone	Consolidated
TTM EPS (₹)	5.7	7.5
TTM Sales (₹ Cr.)	355	371
BVPS (₹.) ⓘ	308.4	315.3
Reserves (₹ Cr.) ⓘ	703	714
P/BV ⓘ	2.74	2.68
PE ⓘ	148.71	112.25

From the Market
52 Week Low / High (₹)	789.05 / 1647.95
All Time Low / High (₹)	789.05 / 2975.55
Market Cap (₹ Cr.)	1,977
Equity (₹ Cr.)	23.4
Face Value (₹)	10
Industry PE ⓘ	57.2

Management X-Ray of Tatva Chintan Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Tatva Chintan Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Tatva Chintan Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	102	90	109	129	203	254	291	428	403	379
Operating Expenses ⓘ	90	75	83	109	170	201	226	322	348	312
Manufacturing Costs	10	5	14	15	20	33	36	65	54	67
Material Costs	64	48	52	68	115	130	148	196	222	168
Employee Cost	8	7	6	10	16	21	24	31	41	55
Other Costs ⓘ	8	15	11	16	18	18	17	30	30	22
Operating Profit ⓘ	11	15	26	21	33	53	65	106	55	67
Operating Profit Margin (%)	11.1%	16.5%	23.7%	15.9%	16.4%	20.8%	22.5%	24.8%	13.6%	17.7%
Other Income ⓘ	1	1	5	5	0	1	5	11	6	8
Interest ⓘ	2	2	2	3	4	4	4	5	9	7
Depreciation ⓘ	2	2	2	4	4	5	7	8	10	26
Exceptional Items ⓘ	0	0	0	0	1	0	0	0	-4	0
Profit Before Tax ⓘ	8	12	27	18	26	44	59	103	39	42
Tax ⓘ	3	4	10	6	6	9	8	7	-2	13
Profit After Tax	6	7	17	12	20	35	51	96	40	29
PAT Margin (%)	5.6%	8.3%	15.9%	9.2%	9.9%	13.8%	17.6%	22.4%	10.0%	7.8%
Adjusted EPS (₹)	2.8	3.7	8.6	5.9	10.1	17.4	25.6	43.3	18.3	12.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	20%	5%	11%	16%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	25	32	50	61	80	114	162	469	505	726
Share Capital ⓘ	8	8	8	8	8	8	20	22	22	23
Reserves ⓘ	17	24	41	53	72	106	142	447	483	702
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	19	21	46	56	71	79	76	106	160	11
Long Term Debt	4	4	17	20	32	39	27	13	4	1
Short Term Debt	16	17	29	36	40	40	49	92	156	10
Trade Payables	19	15	18	24	22	31	47	44	32	44
Others Liabilities ⓘ	1	3	9	5	14	20	35	49	44	29
Total Liabilities ⓘ	65	71	123	146	187	245	320	667	740	810
Fixed Assets
Gross Block	18	22	22	70	73	122	139	186	232	488
Accumulated Depreciation	6	8	10	13	7	11	18	27	36	61
Net Fixed Assetsⓘ	13	14	13	56	67	111	120	160	196	427
CWIP ⓘ	2	5	27	10	6	5	10	51	231	77
Investmentsⓘ	0	1	1	2	1	1	1	1	1	11
Inventories	13	18	20	24	31	59	68	161	151	144
Trade Receivables	25	20	29	36	45	51	90	62	90	68
Cash Equivalents	2	4	18	8	16	10	4	175	39	37
Others Assetsⓘ	10	10	15	10	23	9	27	59	33	47
Total Assets ⓘ	65	71	123	146	187	245	320	667	740	810

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	5	9	24	13	8	25	19	20	24	103
PBT ⓘ	8	12	27	18	26	44	59	103	39	42
Adjustment ⓘ	3	3	2	0	7	8	7	10	16	28
Changes in Working Capital ⓘ	-3	-1	6	0	-20	-20	-38	-75	-23	41
Tax Paid ⓘ	-3	-4	-10	-5	-6	-7	-10	-18	-8	-8
Cash Flow From Investing Activity ⓘ	-5	-8	-25	-24	-17	-40	-21	-197	-101	-121
Capex	-5	-7	-25	-24	-10	-48	-21	-89	-203	-128
Net Investments	0	0	0	0	-7	7	0	-112	97	5
Others ⓘ	0	-1	1	0	0	1	0	5	5	3
Cash Flow From Financing Activityⓘ	0	1	15	1	17	10	-5	235	38	31
Net Proceeds from Shares ⓘ	4	0	0	0	0	0	0	211	0	197
Net Proceeds from Borrowing ⓘ	0	0	0	0	13	13	-9	-13	-13	-9
Interest Paid ⓘ	-1	0	0	-3	-4	-4	-4	-5	-8	-7
Dividend Paid ⓘ	0	0	0	0	0	0	-4	0	-4	-5
Others ⓘ	-3	1	15	4	8	1	13	42	64	-146
Net Cash Flow ⓘ	0	1	15	-10	8	-6	-6	58	-40	13

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	27.78	25.86	42.25	21.61	28.76	36.03	37.16	30.43	8.31	4.77
ROCE (%)	26.78	27.42	38.98	20.43	22.19	26.78	27.88	25.79	7.49	6.91
Asset Turnover Ratio	1.86	1.43	1.2	0.96	1.22	1.17	1.03	0.87	0.57	0.49
PAT to CFO Conversion(x)	0.83	1.29	1.41	1.08	0.4	0.71	0.37	0.21	0.6	3.55
Working Capital Days
Receivable Days	72	83	76	91	72	69	88	65	68	76
Inventory Days	40	58	61	63	50	65	80	98	141	142
Payable Days	96	131	118	114	73	75	96	85	62	82

Tatva Chintan Pharma Chem Ltd Stock News

Tatva Chintan Pharma Chem Ltd FAQs

What is the share price of Tatva Chintan Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Tatva Chintan Pharma on 20-Dec-2024 16:59 is ₹845.2.

What is the market cap of Tatva Chintan Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Tatva Chintan Pharma stood at ₹1,977.1.

What is the P/E ratio of Tatva Chintan Pharma?

The latest P/E ratio of Tatva Chintan Pharma as of 20-Dec-2024 16:59 is 148.7.

What is the P/B ratio of Tatva Chintan Pharma?

The latest P/B ratio of Tatva Chintan Pharma as of 20-Dec-2024 16:59 is 2.74.

What is the 52-week high and low of Tatva Chintan Pharma?

The 52-week high of Tatva Chintan Pharma is ₹1,648 and the 52-week low is ₹789.0.

What is the TTM revenue of Tatva Chintan Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Tatva Chintan Pharma is ₹354.8 ( Cr.) .

About Tatva Chintan Pharma Chem Ltd

The company is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. In addition, the company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. As a manufacturer of specialty chemicals, it focuses on application of its products which form a key ingredient to its customers’ manufacturing and industrial processes. For instance, its SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies.

The company continuously strive to improve its processes and infrastructure to help reduce its impact on the environment and have accordingly, undertaken various ‘green’ chemistry processes such as electrolysis. Considering the wide application of its products, it serve customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. Apart from company’s customers in India, it also export its products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK.

Business area of the company

The company is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals.

Awards, accreditations or recognitions

2006: Received ISO 9001:2015 certification for manufacturing facility at Ankleshwar.
2015: Appreciation certificate from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for Company’s contribution to the revenue and voluntary compliance with tax laws.
2016: Accorded the status of a two star export house from the Directorate General of Foreign Trade, Ministry of Commerce and Industry, Government of India.
2017: Received ISO 14001:2015 and BS OHSAS 18001:2007 certification for our manufacturing facility at Ankleshwar.
2018: Received ISO 9001: 2015 certification for manufacturing facilities at Ankleshwar and Dahej.
2018: Received ISO 14001: 2015 and BS OHSAS 18001:2007 certification for manufacturing facility at Dahej.
2019: R&D facility recognized by the Department of Scientific and Industrial Research, Government of India for the purpose of availing customs duty exemption.
2020: Received ISO 14001:2015 and 45001:2018 certification for manufacturing facility at Ankleshwar.

Major events and milestones

1996: Incorporation of the company.
2004: Received licence to manufacture for sale (or for distribution) of certain drugs from the Food and Drugs Control Administration, Gujarat at our Ankleshwar Manufacturing Facility.
2007: Expansion of manufacturing capacity at Ankleshwar Manufacturing Facility.
2011: Commenced commercial manufacturing of SDAs.
2013: Attained turnover of Rs 500.00 million.
2015: Attained turnover of Rs 1 billion.
2015: Incorporation of Tatva Chintan USA Inc., a wholly owned Subsidiary of Company.
2015: Set up warehousing facility in Netherlands.
2017: Set up Dahej Manufacturing Facility.
2018: Set up R&D facility in Vadodara.
2019: Incorporation of Tatva Chintan Europe BV, a wholly owned Subsidiary of Company.
2020: Completion of ‘Together for Sustainability’ audit.
2020: Conversion of Ankleshwar Manufacturing Facility to a ‘zero liquid effluent discharge facility’.
2020: Attained total revenue of Rs 2 billion.
2020: Increase in manufacturing capacity at our Dahej Manufacturing Facility resulting in an increase in the aggregate manufacturing capacity of our Company from 160 KL and 10 Assembly Lines to 280 KL and 13 Assembly Lines.